Advanced searches left 3/3

Benign Tumors - Crossref

Summarized by Plex Scholar
Last Updated: 02 July 2022

* If you want to update the article please login/register

Ossified choroid plexus papilloma of the fourth ventricle: elucidation of the mechanism of osteogenesis in benign brain tumors

True ossification of benign brain tumors is unusual, but the molecular mechanism for this process is unclear. The authors present a case of ossified plexus papilloma as an embryonic precursor of benign brain tumor formation. A large calcified fourth ventricular tumor with vascular blush and no hydrocephalus was discovered in computed tomography, MRI, and angiography. VEGF-antibody testing was positive. Ostecalcin was present in this ossified tumor but not in samples of nonossified CPPs collected from other patients, according to additional staining. In the ossified CPP, but also in the nonossified CPPs examined, Staining's for osterix and osteopontin was equivocally positive, but not so positive in the nonossified CPP. The presence of osteocalcin in the ossified CPP indicates that bone formation rather than simple calcification occurs more than merely calcification. This is the first systematic immunohistochemical examination of osteogenesis in choroid plexus tumors.

Source link: https://doi.org/10.3171/2013.3.peds12400


Analysis of the effect of intraoperative neuromonitoring during resection of benign nerve sheath tumors on gross-total resection and neurological complications

OBJECTIVE The aim of this research was to investigate the role of intraoperative neuromonitoring during benign peripheral nerve sheath tumor resection in order to achieve gross-total resection and reduction of postoperative neurologic complications. METHODS The data from consecutive adult patients who underwent resection of a benign peripheral nerve sheath tumor at 7 participating hospitals were combined. The association of IONM and GTR, as well as the occurrence of a permanent postoperative neurological complication in the subgroup of patients with tumors involving a motor or mixed nerve were among the secondary results of concern. RESULTS A total of 337 patients who underwent benign nerve sheath tumor resection were included. During the resection of benign nerve sheath tumors, the authors claim that these findings support IONM being regarded as a standard of care, but they do not believe that these results should be used to systematically oppose IONM.

Source link: https://doi.org/10.3171/2020.8.jns202885


Abstract 365: Circulating bone marrow-derived VEGFR-2+ progenitor cells in benign and malignant soft tissue tumors.

Abstract : Circulating endothelial progenitor cells transplanted to the angiogenic vascular system of malignant tumors have been studied as a marker of tumor remission or progression by therapy in lung and breast cancer. We were keen to investigate the presence of bone marrow derived cEPCs in soft tissue malignancies and correlate treatment effectiveness. Conclusions: The number of hematopoietic stem cell cells in sarcoma and desmoid patients was dramatically higher in sarcoma and desmoid patients compared to GIST and healthy controls. The percentage of VEGFR-2+ cells in sarcoma of 0. 179 percent vs. healthy controls of 0. 018 percent equals 0. 018 percent. Values for desmoid patients were similar to sarcoma, while GIST patients had values similar to healthy patients. Compared to sarcoma and GIST patients, Ang-2 levels before therapy were significantly lower in healthy controls and desmoids. Patients without evidence of tumor recurrence had normal cEPC values at post-treatment controls, while those with progressive disease had elevated cEPC values. Compared to healthy people and patients with GIST, this research shows an increasing mobilization of cEPCs in sarcoma and desmoids tumors. cEPCs recruited for vaping and paracrine effects play a different role in the various subtypes of human soft tissue tumors.

Source link: https://doi.org/10.1158/1538-7445.am2013-365


Multiphasic CT-Based Radiomics Analysis for the Differentiation of Benign and Malignant Parotid Tumors

paraphrased tumors differentiation between benign parotid tumors and malignant parotid tumors is the aim of this research, which aims to investigate the use of machine learning models based on medical-radiological data and multiphasic CT radiomics characteristics. Methods This retrospective review included 312 patients who underwent multiphasic enhanced CT examinations, which were randomly divided into preparation and test sets. To obtain minority class samples in the education sample, the synthetic minority oversampling procedure was used. Meanwhile, the modeling results of various radiomics models based on single phase and multiphase were compared to determine which model construction technique and phase were more discriminative. In the test set, the combined model based on LR had a lower AUC than the optimal radiomics model, but no statistically significant difference remained.

Source link: https://doi.org/10.3389/fonc.2022.913898


Abstract 3011: MicroRNA expression profiles in benign and aggressive canine mast cell tumors

Canine mast cell tumors, a common cutaneous tumor of dogs, are characterized by a mild, locally invasive, highly metastatic disease that is not responsive even to multimodality therapy. We suspect that high grade MCTs have a distinctive miRNA expression signature distinct from that found in benign MCTs, contributing to their aggressive behaviour. Methods: Total RNA was isolated by the Trizol technique from 12 biologically poor grade and 12 biologically high grade. The preamplified cDNA analysis of Mature miRNA expression was done using TaqMan Low Density Arrays, interrogating the expression profile of 378 miRNAs, 151 of whom mature sequences are 100% conserved between human and dog, according to Mature miRNA expression. Normalization was performed with the small nuclear RNA U6 and microRNA expressions were calculated using the comparative Ct method. Compared to low grade tumors, miRNAs of known importance in human tumorigenesis, including many members of the miR 17-92 cluster and its predecessor, were noticeably overexpressed in high grade tumors, especially among those of the miR-106b-25 cluster and its paralog. Conclusion: Our results show that specific miRNAs play a role in the biologically active canine MCT phenotype. Unique miRNA expression signatures in high grade tumors were found in comparison to low grade tumors, according to hierarchical clustering. Characterization of miRNA expression in canine MCTs will aid in better understanding the disease's path and the possibility of identifying diagnostic/prognostic factors and therapeutic targets.

Source link: https://doi.org/10.1158/1538-7445.am10-3011


Abstract 2159: Genomic characterization of benign and malignant thyroid tumors

Abstract Summary: Thyroid cancer cells contain multiple genomic abnormalities that promote malignant transformation. Methods: We estimated copy number across the genome on 39 thyroid tumors with matched normal tissue on 39 thyroid tumors with matched normal tissue, which included 14 benign tumors and 25 malignant tumors in a 2005 version of the Illumina HumanHap550 BeadChip. Results: 39 thyroid tumor tumors were identified by the comprehensive genetic profile of 39 thyroid tumors, as well as tumor-specific somatic change evaluated using matched normal thyroid tissue as a comparison. With tighter control of the false discovery rate, significant alterations averaged 32 CNVs in benign FAs, and 8 in malignant thyroid cancer, with 17 rises in FAs and three rises in cancers, 2. 9 losses in FAs, and 4. 4 million in cancers. To identify genes for which copy number was related to tumor type, we used empirical Bayes modified ANOVA. In FAs, chromosome 12 increases were more common in FAs than in cancer. Overall, follicular adenomas demonstrated significantly higher rates of copy number variation than the two malignant tumor subtypes investigated, i. e. Conclusions: Benign and malignant thyroid tumors may have characterized and distinguishable genomic profiles. We'll continue to perform transcriptome-wide expression analysis on the same tissue sample set used for the SNP array study and perform an integrated analysis combining DNA genetic changes and differential gene expression to help identify candidate molecular differences in distinguishing benign thyroid lesions.

Source link: https://doi.org/10.1158/1538-7445.am10-2159


Abstract 1068: Cooperation between BRCA1 and Aurora A kinase regulates in vitro crisis in epithelial cells derived from benign ovarian tumors

We used an in vitro cell culture model in which benign epithelial ovarian tumor explants were transfected with an expression vector for SV40 Large T Antigen, allowing for bypass of senescence due, in part, to p53 and Rb inhibition by this antigen. We previously reported that such cells will eventually reach a crisis event that is linked to a cell cycle arrest at the M phase and is independent of telomere attrition. In cells approaching a crisis, Aurora A kinase activity and expression is up-regulated. Aurora A over-expression resulted in reduced BRCA1 levels, resulting in increased tetraploidy and aneuploidy, which were attributed to cells' resistance to a ploidy-associated disease epidemic. Following the downdown of Aurora A kinase using siRNA, BRCA1 expression increased, indicating an inverse association between expression levels of these two proteins. Inhibition of Aurora A in cultured ovarian cystadenomas is a threat to cell growth and a concomitant decrease in tetraploidy. We tested the possibility that this was related to an increase in crisis-related apoptosis by knocking down Aurora A kinase's siRNA technologies in cells facing crisis, followed by western blotting using antibodies against PARP and a fragment of the cleaved CASPASE 7 fragment. Aurora A's role in BRCA1 expression levels in cells facing a ploidy dependent crisis could be a novel one, according to our findings. This may help explain the rise in near polyploidy associated with high grade ovarian carcinomas in part, as well as other epithelial cancer pathogenesis.

Source link: https://doi.org/10.1158/1538-7445.am10-1068


Abstract LB-271: Benign ovarian serous tumors: A redefining moment

Abstract Obvarian cancer is a significant health issue and the fifth leading cause of cancer death in women. Although a number of candidate precursor lesions have been identified, it is difficult to determine the true contribution of these precursor lesions to the onset of ovarian cancer. About 80% of all ovarian tumors and the serous subtype account for approximately 53% of ovarian epithelial tumors in the United States, according to 70 percent. Serous cystadenomas and cystadenofibromas are common ovarian tumors, accounting for 25% of all benign ovarian tumors and 58% of ovarian serous tumors. Although there are no concrete molecular or histopathological evidence, ovarian serous cystadenomas and cystadenofibromas have been attributed to serous borderline tumors and low grade serous carcinomas, according to several. We conducted copy number and identity verification on 14 ovarian serous cystadenofibromas and 20 ovarian serous cystadenofibromas using the ultra high-resolution Affymetrix SNP6. 0 microarray and the high-resolution Molecular Inversion Probe assay. Each tumor was microdissected to allow the analysis of tumour epithelium and adjacent stroma with matching lymphocyte DNA for each patient. These findings are in accordance with Seidman and Mehrotra's assertion that the bulk of benign ovarian serous tumors are characterized as potentially cystically dilated glandular inclusions and misclassified fibromas with epithelial inclusions. This will significantly reduce the incidence of the serous subtype in ovarian epithelial tumors and change the role of the other epithelial subtypes, with definite implications for studies of serous ovarian u201c prevalence u201d lesions.

Source link: https://doi.org/10.1158/1538-7445.am2011-lb-271


Decreased steroidogenic enzyme activity in benign adrenocortical tumors is more pronounced in bilateral lesions as determined by steroid profiling in LCMSMS during ACTH stimulation test

Using serum steroid profiling in LC-MS/MS in basal state and after ACTH 1-24 stimulation, this research was designed to determine steroidogenesis enzymes function in unilateral and bilateral benign tumors. In LC-MS/MS in basal state and following ACTH 1-24 stimulation in 35 patients with bilateral adrenocortical tumors, 38 patients with unilateral tumors, and 37 control subjects, a serum profile of seven consecutive adrenal steroids was determined. Results: The amplitude of reaction to ACTH in BL was higher in BL than in UL and CT, with a higher amplitude for the seven steroids assayed. Even after comparing patients on adrenal capacity, the difference between BL and UL remained. In comparison to both UL and CT, the enzymatic activity of CYP11B1 on the glucocorticoids pathway was much reduced in BL. CYP11B2 and CYP17A1-17,20 lyase was also lower in BL than UL and CT, as on mineralocorticoids and androgens pathways, as well as in BL.

Source link: https://doi.org/10.1530/ec-22-0063


Abstract 702: BRAF V600E mutation in benign and malignant epithelial odontogenic tumors

Abstract The classification of ameloblastoma in multicystic or unicystic forms has been associated with its clinical behavior. In addition, we investigated whether the BRAFV600E mutation appears in odontogenic carcinomas. BRAFV600E mutation, specifically 5/6 unicystic, 7/9 multicystic, and 2/2 desmoplastic ameloblastomas were found in Fourteen out of 17 ameloblastomas. BRAFV600E mutation was found in 4/11 malignant tumors, including 3/8 ameloblastic carcinomas and 1/1 clear cell odontogenic carcinoma, although the two ghost cell odontogenic carcinomas did not have this mutation. In ameloblastoma, the SMOF412E mutation was not present in ameloblastoma. The BRAFV600E mutation was less frequent in odontogenic carcinomas than in ameloblastomas. Our results point to the possibility of personalized, molecular targeted therapy for ameloblastomas and ameloblastic carcinomas harboring the BRAFV600E mutation. 2017-1701 : AM2015-702, doi:10. 1158/1542-7445. AM2015-702, AM2015-702; 7396; advance 702. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015: Birmingham, PA; 2017 Sep 18-22; Philadelphia, PA; 65: Abstract nr 702. doi:10. 1158/1602; 2015:60;85: AM2015-702. doi: 10. 1015.

Source link: https://doi.org/10.1158/1538-7445.am2015-702

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions